By: IPP Bureau
Last updated : May 01, 2026 5:41 pm
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Fabtech Technologies Limited reported strong financial performance for FY26, with consolidated total income rising 28.4% year-on-year to Rs 431.33 crore, driven by robust execution across pharmaceutical, healthcare and biotech infrastructure projects globally.
The company’s EBITDA increased 18.29% to Rs 55.56 crore, while operational profit after tax grew 17.4% to Rs 36.6 crore during the financial year.
Fabtech said its order book stood at over Rs 900 crore as of March 31, 2026, providing execution visibility for the next 18–24 months. The company expects 25–30% growth ahead, supported by expanding opportunities across the Middle East, North Africa and emerging African markets.
During its Q4 FY26 earnings conference call, management highlighted that the UAE and Saudi Arabia continue to remain core strategic markets, while Kenya and West Africa are emerging as major long-term growth regions for pharmaceutical manufacturing infrastructure.
The company secured several new projects during the year, including vaccine and veterinary pharmaceutical facilities in Saudi Arabia and North Africa, as well as turnkey tablet and capsule manufacturing facilities in West Africa.
Fabtech also said it is increasing focus on larger and more integrated turnkey projects, including pre-engineered buildings (PEB), solar integration and end-to-end pharmaceutical manufacturing infrastructure.
The company strengthened its balance sheet during FY26 through a strategic equity infusion of nearly Rs 230 crore following its IPO. Cash and bank balances rose sharply to Rs 208.57 crore.
Management acknowledged that geopolitical tensions and supply-chain disruptions in the Middle East impacted margins during the year due to rising freight, raw material and execution costs. However, it said the company’s localization strategy in UAE and Saudi Arabia helped maintain project execution and client commitments despite operational challenges.